Alexander Sapir
Vorstandsvorsitzender bei FULCRUM THERAPEUTICS, INC.
Vermögen: 309 870 $ am 30.04.2024
Aktive Positionen von Alexander Sapir
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PHASEBIO PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 12.02.2020 | - |
Independent Dir/Board Member | 12.02.2020 | - | |
FULCRUM THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.07.2023 | - |
Vorstandsvorsitzender | 01.07.2023 | - | |
Präsident | 01.07.2023 | - | |
Finanzdirektor/CFO | 01.07.2023 | 07.08.2023 | |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Direktor/Vorstandsmitglied | 10.06.2019 | - |
Vorstandsvorsitzender | 10.06.2019 | - |
Karriereverlauf von Alexander Sapir
Ehemalige bekannte Positionen von Alexander Sapir
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
DOVA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.03.2017 | 01.04.2019 |
Vorstandsvorsitzender | 01.01.2017 | 01.12.2018 | |
Präsident | 01.01.2017 | 01.12.2018 | |
UNITED THERAPEUTICS CORPORATION | Vertrieb & Marketing | 01.01.2006 | 01.05.2016 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Vertrieb & Marketing | 01.01.2003 | 01.01.2005 |
Ausbildung von Alexander Sapir
Harvard Business School | Masters Business Admin |
Franklin & Marshall College | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Vereinigtes Königreich | 2 |
Operativ
Director/Board Member | 4 |
Chief Executive Officer | 3 |
President | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
UNITED THERAPEUTICS CORPORATION | Health Technology |
PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
FULCRUM THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Alexander Sapir
- Erfahrung